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The dual regulation of cyclic AMP accumulation was studied in rat prostatic epithelial cells incubated with 
somatostatin, vasoactive intestinal peptide (VIP), and the fl-adrenergic agent isoproterenol. Somatostatin 
noncompetitively inhibited the stimulatory effect of VIP and isoproterenol, but it did not alter basal cyclic 
AMP levels. In addition to the multifactorial regulation of the cyclic AMP system in rat prostatic epitheli- 
um, these results uggest that somatostatin may play a physiological role at this level. 
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1. INTRODUCTION 
The prostate is considered to be controlled 
primarily by androgens although it seems to 
become increasingly evident hat some peptide hor- 
mones and neuromolecules could also be involved 
at this level [1]. Previous studies from our 
laboratory have shown that the prostatic cyclic 
AMP system is activated by a variety of agonists 
including classical neurotransmitters such as /Y- 
adrenergic agonists [2] as well as more complex 
agents such as the neuropeptide vasoactive in- 
testinal peptide (VIP) [3]. In contrast, the 
regulatory role of hormones or other factors 
negatively coupled to adenylate cyclase has not 
been as extensively investigated since only 
muscarinic receptors are known to lead to negative 
responses in this gland [4]. 
Recent immunohistochemical studies have 
demonstrated the presence of somatostatin 
endocrine-paracrine c lls in the prostate gland 
[5,6] thus making possible a physiological involve- 
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ment of this hormone in prostatic growth and 
functions. Somatostatin is a well known inhibitor 
of cyclic AMP synthesis timulated by a number of 
agents including VIP [7] and catecholamines [8] in 
other tissues. The present study examined the ac- 
tion of somatostatin, both alone or in combination 
with VIP and the /Y-adrenergic agonist 
isoproterenol, upon cyclic AMP accumulation i  
isolated epithelial cells of rat ventral prostate. 
Consequently, the results extend present 
knowledge on the dual regulation of prostatic 
cyclic AMP and represent the first indication of a 
direct action of somatostatin this gland. 
2. MATERIALS AND METHODS 
Synthetic rat VIP was from Peninsula (St. 
Helens, England), 3-isobutyl-l-methylxanthine 
from Aldrich (Milwaukee, WI), and DL-iso- 
proterenol, bacitracin and bovine serum albumin 
from Sigma (St. Louis, MO). Somatostatin was a 
generous gift from Serono (Madrid, Spain). 
The procedures for preparing epithelial cells 
from the ventral obes of rat prostate [3,9] and for 
incubating the cells in order to study cyclic AMP 
accumulation [3] have been described. Cell- 
associated endogenous materials that could in- 
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terfere with results were removed by preincubating 
the isolated cells for 30 min at 37°C in 9°70 NaCl, 
followed by washing. More than 9007o f the cells 
were viable as measured by exclusion of trypan 
blue dye. Protein determination was performed us- 
ing bovine serum albumin as a standard [10]. The 
basal medium used in all experiments consisted of 
35 mM Tris-HCl (pH 7.5), 50 mM NaCl, 1.4% 
(w/v) bovine serum albumin, 1 mg/ml  bacitracin, 
and 0.2 mM 3-isobutyl-l-methylxanthine. Cyclic 
AMP levels were determined after a 60-min in- 
cubation of ceils (0.3 mg protein/ml) at 15°C in 
the absence or presence of VIP, isoproterenol and 
somatostatin ata total volume of 0.5 ml. The reac- 
tion was stopped by the addition of 2.5 ml cold 
methanol, and the suspension was centrifuged for 
10min at 2000 x g. The supernatant was 
evaporated for the determination of cyclic AMP 
[11]. The data shown represent means +_ SE of ex- 
periments performed in triplicate. 
3. RESULTS 
As shown in fig.l, 100 nM somatostatin in- 
hibited in a non-competitive manner the 
stimulatory effect of VIP upon cyclic AMP ac- 
cumulation in rat prostatic epithelial cells without 
altering the basal level. The effect of a maximally 
active (100 nM) VIP concentration was reduced by 
about 60% in the presence of somatostatin. Half- 
maximal stimulation (EDs0) of cyclic AMP was 
elicited by about 1 nM VIP both in the absence 
and presence of the inhibitory hormone. 
A qualitatively similar pattern was obtained 
when studying the action of somatostatin on the 
cyclic AMP response to the B-adrenergic agent 
isoproterenol (fig.2). The EDs0 was observed at 
about 100 nM isoproterenol and did not vary with 
the addition of 100 nM somatostatin whereas this 
concentration of the inhibitory hormone resulted 
in a 75070 decrease of the cyclic AMP response at 
the maximally effective dose (100/zM) of the ~'- 
adrenergic agonist. 
The data in fig.3 show that somatostatin did not 
alter basal cyclic AMP levels in rat prostatic 
epithelial cells throughout the whole range of con- 
centrations studied (up to 3/zM). However, the in- 
hibitory role of this hormone was shown to depend 
on the dose used upon both VIP- and isoprotere- 
nol-stimulated cyclic AMP levels. The stimulatory 
effect of an intermediate concentration (10 nM) of 
VIP was completely abolished by high concentra- 
tions of somatostatin, half-maximal inhibition 
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Fig.1. Cyclic AMP accumulation in rat prostatic 
epithelial cells incubated with increasing concentrations 
of VIP in the absence (e) or presence (o) of 100 nM 
somatostatin. Values are the means _+ SE of six triplicate 
experiments. 
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Fig.2. Cyclic AMP accumulation in rat prostatic 
epithelial cells incubated with increasing concentrations 
of isoproterenol in the absence (e) or presence (o) of 
100 nM somatostatin. Values are the means _+ SE of six 
triplicate xperiments. 
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Fig.3. Cyclic AMP accumulation in rat prostatic 
epithelial cells incubated with increasing concentrations 
of somatostatin i  the absence (A) or presence of either 
l0 nM VIP (e) or 1/zM isoproterenol (-,). Values are 
the means _+ SE of six triplicate xperiments. 
(IC50) being observed at about 70 nM. In concert 
with these results, increasing doses of somatostatin 
caused a continuous decrease of isoproterenol 
(1/zM)-stimulated cyclic AMP levels (IC50 = 1/~M) 
although absolute blocking of the stimulatory 
response could not be obtained at a somatostatin 
concentration as high as 3/zM. 
4. DISCUSSION 
This study indicates that somatostatin i hibits 
both VIP- and isoproterenol-stimulated cyclic 
AMP accumulation i rat prostatic epithelial cells 
by a noncompetitive mechanism without altering 
the basal cyclic AMP content. It represents the 
first description of the involvement of somato- 
statin in the cyclic AMP system of the prostatic 
epithelium. The present data together with 
previous results on the characterization of 
somatostatin-containing cells in the prostate gland 
[5,6] suggest a physiological involvement of the 
hormone acting in a local manner at this level. Fur- 
thermore, the increase of the number of hormones 
and neurotransmitters voking a response from the 
cyclic AMP system [2-4] implies that the control 
of prostatic epithelial function may be exceedingly 
complex, involving not only androgens but also 
many other factors. 
The characteristics of the inhibition by 
somatostatin of the VIP- and B-adrenergic-induced 
cyclic AMP accumulation i rat prostatic epithelial 
cells are similar to those previously described in 
other systems uch as pituitary tumor cells [7] and 
gastric epithelial glands [8]. Somatostatin was 
without effect on basal cyclic AMP levels whereas 
VIP and isoproterenol exerted a permissive role 
upon the somatostatin inhibitory response. Fur- 
thermore, somatostatin decreased maximal 
stimulation of cyclic AMP accumulation by both 
VIP and isoproterenol but did not alter their 
potencies. On the other hand, the observed 
changes in cyclic AMP levels are likely to result 
from modulation of adenylate cyclase activity 
since the experiments were performed in the 
presence of a high concentration of phosphodi- 
esterase inhibitor. In fact, accumulating evidence 
indicates that regulation of adenylate cyclase may 
be the main mechanism for somatostatin actions in 
many cell types [12]. Therefore, the present results 
in rat prostatic epithelial cells suggest the existence 
of somatostatin receptors coupled to adenylate 
cyclase in an inhibitory manner, probably through 
a guanosine nucleotide-binding protein [13]. 
However, further studies are required to under- 
stand the precise role of cyclic AMP in the action 
of somatostatin at this level since a cyclic AMP- 
independent mechanism may also be involved in 
some somatostatin effects in various tissues [7]. 
Finally, the exact nature of somatostatin receptors 
in prostatic epithelium remains to be established 
since biologically active somatostatin receptors ap- 
pear to exist in both plasma membrane and in- 
tracellularly in various systems [14]. Thus, at the 
present ime, we cannot determine whether soma- 
tostatin exerts the studied effects by first interac- 
ting with a membrane site or after penetrating into 
the prostatic epithelial cells. 
ACKNOWLEDGEMENTS 
This research was supported by grants from the 
Comisi6n Asesora de Investigaci6n Cientifica y 
T6cnica and the Fondo de Investigaciones 
Sanitarias. 
75 
Volume 218, number I FEBS LETTERS June 1987 
REFERENCES 
[1] Webber, M.M. (1981) in: The Prostatic Cell: 
Structure and Function, Part B (Murphy, G.P. et 
al. eds) pp.63-68, A.R. Liss, New York. 
[2] Carmena, M.J., Sancho, J.I. and Prieto, J.C. 
(1986) Biochem. Int. 13, 479-485. 
[3] Carmena, M.J. and Prieto, J.C. (1983) Biochim. 
Biophys. Acta 763,414-418. 
[4] Carmena, M.J. and Prieto, J.C. (1985) Biosci. 
Rep. 5, 791-797. 
[5] Sant'Agnese, P.A. and Jensen, K.L.M. (1984) 
Arch. Pathol. Lab. Med. 108, 693-696. 
[6] Pekary, A.E., Yamada, T., Sharp, B., Bhasin, S., 
Swerdleff, R.S. and Hershman, J.M. (1984) Life 
Sci. 34, 939-945. 
[7] Dorflinger, L.J. and Schonbrunn, A. (1983) 
Endocrinology 113, 1551-1558. 
[8] Boige, N., Dupont, C., Chenut, B., Gespach, C. 
and Rosselin, G. (1984) Eur. J. Clin. Invest. 14, 
42-48. 
[9] Jung-Testas, I., Groyer, M.T., Bruner-Lorand, J0, 
Hachter, O., Baulieu, E.E. and Robel, P. (1981) 
Endocrinology 109, 1287-1289. 
[10] Lowry, O.H., Rosebrough, N.J., Farr, A.L. and 
Randall, R.J. (1951) J. Biol. Chem. 193,265-275. 
[111 Gilman, A.G. (1970) Proc. Natl. Acad. Sci. USA 
67, 305-312. 
[12] Koch, B.D. and Schonbrunn, A. (1984) 
Endocrinology 114, 1784-1790. 
[13] Dolphin, A.C. (1987) Trends Neurosci. 10, 53-58. 
[141 Steiner, C., Dahl, R., Sherman, N., Trowbridge, 
M., Vatter, A., Robbins, R. and Draznin, B. (1986) 
Endocrinology 118, 766-772. 
76 
